- cafead   Nov 15, 2024 at 11:32: AM
via Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes in a midphase trial, positioning the biotech to advance the ex-Novartis candidate toward late-stage development in 2025.
article source
article source